Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means the agency’s own highest classification or reported deaths or serious injuries, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
Oregon Compounding Centers is recalling Copper Sulfate injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Hydroxocobalamin (B12) injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Trience 8mg/2.0mL injectable syringes due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling specific lots of injectable Papaverine HCL/Phentolamine/Prostaglandin due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling 145 vials of Chorionic Gonadotropin due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Dexamethasone injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Papaverine/Phentolamine/Prostaglandin injectable vials due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Lidoaine HCL solution for irrigation due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Papaverine HCL/Phentolamine/Prostaglandin injectable vials due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Alprostadil injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Pyridoxine HCL injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Mitomycin injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Vancomycin injectable syringes due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Dexpantenol injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Testosterone Cypionate injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Prednisolone Sodium Phosphate ophthalmic drops due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Papaverine HCL/Phentolamine Mes/Prostaglandin injections due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Ganciclovir syringes due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling injectable ascorbic acid vials because quality control issues observed during an FDA inspection present a potential risk to sterility assurance.
Oregon Compounding Centers is recalling Sodium Chloride Inhalation 7% solution due to quality control issues affecting sterility assurance.
Apotex Inc. is recalling Candesartan Cilexetil Tablets, 4 mg, because out-of-specification results were observed for specific impurities and total impurities.
Sun Pharma Global Inc. is recalling specific batches of Venlafaxine Hydrochloride Extended-Release Tablets because they failed dissolution specifications and a 12-month stability time point.
Physicians Total Care is recalling specific lots of Cephalexin Monohydrate Capsules because the active ingredients were not manufactured with good manufacturing practices.
Pharmaceutical Associates Inc. is recalling 9,640 unit dose cups of Cyproheptadine HCl Syrup because an unidentified impurity exceeded specifications during stability testing.
Obagi Medical Products is recalling 975 bottles of Obagi Nu-Derm Clear due to a labeling mix-up where Exfoderm Forte contents were shipped.